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Background: The introduction of biological therapy drugs contributes to changing the natural course of the disease in cases of severe JIA. Objectives: To clarify impact of tocilizumab on the course of JIA. Methods: Of 117 children with JIA being under observation for the last five years 35% receive biologic therapy (3 etanercept, 21 adalimumab, 11 tocilizumab) during 1-5 years. Retrospective analysis of the data from clinical, laboratory and instrumental studies in the dynamics of the TCZ treatment of patients with JIA was made.
Results: Among children treated with TCZ 63,6% were sJIA cases, 63,6% were female. Age of onset 6,1±4,7y (6m-10,5y), all had acute onset, hyperthermia, severe pain syndrome, exudative arthritis in all pJIA cases and half of sJIA cases. ESR 39,7±11,2 mm/h, CRP 53,8±16,1 mg/L, all patients had anemia, leukocytosis and were seronegative for RF and anti-CCP, 3 of pJIA patients revealed ANA (1:1200-2400), IL-6 19,78±6,7 pg/ml. Before biological therapy has begun, SJIA courses were continuously relapsing in all cases with 4,7±2,1 exacerbations per y; during the 1st y of illness 8 cases run with coxitis, 7-cervical spine involvement, 9-wrists damage. All patients received CS therapy before initiating TCZ, 45,4% of them with pulse therapy, all marked by the inability to minimize the CS dose, all received 2-4 DMARDs in high doses. 2 patients received adalimumab before TCZ treatment. Elapsed time from the onset to biological agent prescription was 5,37±5,1 years. At the start of biological therapy JADAS was 19,6±5,7, stunted growth -1,88±0,3 σ, according to densitometry, osteoporosis took place in every case (Z=-2,7±1,1). After 6 month JADAS was 1,8±1,1, ESR and CRP normalized, IL-6 rate remained high in 36% cases. After 1 year the severity of osteoporosis decreased (Z = -1,17±0,8), bone deficiency depended on duration of TCZ exposure (r = -0,72) and on the elapsed time from onset of JIA before the start of biological therapy (r = -0,84). The mean increase in height was 7.73 cm/patient-year (+1±0,8 σ). Stunted growth depended on the duration of the TCZ course (r=-0,81) and the elapsed time from the onset of the disease to the start of biological therapy (r=-0,72). After 1 y of TCZ all children had normal weight and BMI for age (19,89±1,9) . After 1-5 ys of treatment JADI was evaluated 2,1±2,9 (0-7), the degree of joint damage didn't depend on the duration of the biological therapy (r=0,24) and correlated with the time elapsed from the onset of the disease before treatment (r =0,59). During the treatment, exacerbations were marked only in 1 case, adverse events in 3 cases (skin infections, leukopenia). TCZ therapy allowed to completely discontinue CS in 63,6% cases, minimize them to 4 mg/day in others, DMARDs are discontinued in 9% cases. Conclusions: Administration of TCZ is rather effective towards the drug induced remission even in long-time JIA process, but the least joint damage, osteoporosis and stunted growth can be obtained with earlier tocilizumab prescription. Reclassification of patients according to specific clinical and immunological features leads to optimization of the selection of targeted therapy. Background: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory disorder that has sterile bone inflammation as a main phenotypic feature. Diagnosis of CRMO is based on typical clinical and radiologic findings and presence of some inflammatory markers. Plain radiographs, technetium bone scan and MRI may be used for diagnosis of children with suspected CRMO. Despite data for other imaging methods in chidren with CRMO, little information is available regarding the bone mineral density. Objectives: The aim of the study was to evaluate bone mineral density (BMD) findings in children with CRMO at time of diagnosis. Methods: The medical records of children with CRMO were reviewed retrospectively. Children who met Bristol diagnostic criteria were included in the study. Clinical and laboratory findings, bone scan and MRI features were analyzed. Bone mineral density was measured by DEXA technique at femoral neck and lumbar spine regions; a Z-score< −2 was considered as osteoporosis. Results: A total of 6 patients, one girl and 5 boys, with a median age of 10 years (4 -14 years) and a median follow-up period of 38.5 months (3 -72 months) were included in the study. MRI and whole body technetium bone scan were performed at 6 and 4 children, respectively and detected at least two lesions MRI or bone scans. Osteoporosis was detected in 5 patients at diagnosis. Bone mineral density Z-scores were median -2.9 [-4.9±(-2,4)] and -2.9 [-4,1 -(-1,8) ] at femoral neck and lumbar spine, respectively. Conclusions: Osteoporosis is common in children with CRMO, it may be related with disease spectrum. Evaluation of bone mineral density abnormalities at time of diagnosis and during therapy may be a part of primary care in children with CRMO. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4452 
